This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of LY2523355 in Patients With Solid Cancer (2523355-001)

This study has been completed.
Information provided by (Responsible Party):
Kyowa Hakko Kirin Co., Ltd Identifier:
First received: May 17, 2011
Last updated: January 25, 2013
Last verified: January 2013
The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.

Condition Intervention Phase
Solid Tumors Drug: LY2523355 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of LY2523355 in Patients With Solid Cancer

Further study details as provided by Kyowa Hakko Kirin Co., Ltd:

Primary Outcome Measures:
  • Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0
  • Number of patients with adverse events

Secondary Outcome Measures:
  • Pharmacokinetics
    Plasma concentration of LY2523355 and metabolite

  • Antitumor effect
    Response evaluation criteria in solid tumors

Enrollment: 18
Study Start Date: May 2011
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LY2523355 Drug: LY2523355
Days 1, 2, and 3 in a cycle that consists of 21-days


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological and/or cytological evidence of solid tumors
  • A diagnosis of advanced and/or metastatic solid tumors
  • Patients who are refractory to standard therapy or for which no proven effective therapy exists
  • Written informed consent
  • Appropriate bone marrow, hepatic and renal functions
  • ECOG PS =< 1

Exclusion Criteria:

  • Have serious preexisting complication
  • Have active infection which requires intravenous antibiotics
  • Have symptomatic central nervous system metastases
  • Have current acute or chronic leukemia
  • Have had an autologous or allogenic hematopoietic stem cell transplantation
  • Have active multiple cancers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01358019

Tokyo, Japan
Sponsors and Collaborators
Kyowa Hakko Kirin Co., Ltd
Study Director: Senior Manager Kyowa Hakko Kirin Co., Ltd
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kyowa Hakko Kirin Co., Ltd Identifier: NCT01358019     History of Changes
Other Study ID Numbers: 2523355-001
Study First Received: May 17, 2011
Last Updated: January 25, 2013 processed this record on August 21, 2017